Istituto di Cristallografia - CNR

Sito web ufficiale dell'Istituto di Cristallografia del Consiglio Nazionale delle ricerche

Maria Moccia Pagina Personale

di · February 5, 2020

Maria Moccia
Tel: +39 06 90672 676
E-mail: maria.mocciaATic.cnr.it – maria.mocciaATcnr.it
Indirizzo: Via G.Amendola 122/O 70126, Bari, Italy

 

Qualifica Attuale :  Staff Researcher

 

Curriculum Vitae :

2003: MSc Organic Chemistry, University of Naples.
2007: PhD Organic Chemistry under the supervision of Prof. C. Pedone, Department of Biological Science, University of Naples. During PhD worked at Edinburgh University under the supervision of Prof Mark Bradley on “Non enzymatic method for single nucleotide polymorphism analysis”.

2008: Post-doctoral Research Fellows at IBB-CNR on project entitled “Peptide-PNA chimera mimetic of Ni superoxide dismutase (SOD) binding site”.
2009-2011: Awarded Marie Curie fellowship (CEMP) : Development of novel PNA based molecular probes for the detection of c-Myc mRNA.
2011-2012: Senior Post-doctoral Research Fellow in Chemistry at RCSI founded by TIDA and SFI.
2013-nowdays: Researcher at IC-CNR

 

Ambiti di Ricerca:

Design, synthesis and development of peptide nucleic acid as miRNA mimics for therapeutic applications.
Peptide synthesis, oligonucleotide synthesis DNA, PNA, DNA/PNA chimera.

Design, synthesis and characterization of natural and unnatural peptides for drug discovery, therapeutics, diagnostic and sensing applications.

Development of Diversity Oriented Synthesis using sugar (d-deoxy ribose) based polyfunctional scaffolds.
Asymmetric Organocatalysis: bifunctional and phase transfer catalysis (PTC ) to design new synthetic strategies  for active pharmaceutical ingredients (API).
Direct sulfonylation of activated olefins.

 

Projects :
1) Horizon 2020– PON 2014/2020-
Study, design and development of an innovative kit for early and non-invasive diagnosis of coeliac disease by genetic markers.
The project is developed together with two industrial Partners: BIOFORDRUG srl Bari, and Biochemical Systems International (BSI) Arezzo.
The aim of the project is the development  of  an non invasive, innovative kit for the early diagnosis of coeliac disease using genetic biomarkers such as miRNAs.
2) Fondazione con il SUD-Bando Sviluppo del Capitale Umano ad alta Qualificazione 2011.
2011-DPR-20; Titolo “Verso la medicina personalizzata: Sviluppo di nuove molecole selettive perla cura del Neuroblastoma”.
The aim of the project was the design, synthesis and biological assessment of novel PNA-34a molecules for the treatment of Neuroblastoma.
3) Project Coordinator and manager of H2020-MSCA-RISE-2014-645317- Chemo-enzymatic Manufacturing routes to high value compounds (ChemoEnz).  01/06/2015-31/05/2017
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to develop a platform of “green” chemoenzymatic methods for the production of high value active pharmaceutical ingredients – both those currently on the market, and those in development pipelines of the Pharma industry. The partners will exemplify the use of the platform through its application in the production of 4 drugs currently on the market – namely Duloxetine, Atomexetine, Ramosetron and Paricalcitol. In order to achieve this objective the proposal brings together 3 partners with complementary skills:
IC-CNR: Protein crystallography, organo catalysis; Kelada Pharmachem: Phase transfer catalysis/organo catalysis/scale-up of chemical processes Cerbios Pharma: Biocatalysis and fermentation methodologies for drug production.
Other information about the project:
http://cordis.europa.eu/project/rcn/194306_en.html
https://www.openaire.eu/search/project?projectId=corda__h2020::79a434184d071dea7f9a0ea8f482841c
https://www.highbeam.com/doc/1G1-420720496.html
http://www.fabiodisconzi.com/open-h2020/projects/194306/index.html

 

Pubblicazioni Scelte :

1. Bencivenni G, Moccia M., A Ravelli, MWG Healy, BG Kelly,Adamo M.F.A  First Enantioselective Synthesis of Gingesulfonic Acids and Unequivocal Determination of their Absolute Stereochemistry. Organic & Biomolecular Chemistry, 2020, in press

2. Piacenti V., Langella E., Autiero I., Nolan J.C., Piskareva O., Adamo M.F.A., Saviano M., Moccia M.*, A combined experimental and computational study on peptide nucleic acid (PNA) analogues of tumor suppressive miRNA-34a, Bioorganic Chemistry, 2019,

3. Moccia M.*, Adamo MFA, Saviano M., Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity 2016, . 5 (3), e1107176, pp. 1-15.

4. Adamo MFA , Kelly B., Moccia M.,Recent advances in the preparation of active pharmaceutical ingredient (S)-Pregabalin. Chemistry Today 2016, 34, 54-57.

5. Del Fiandra, C., Moccia, M.; Adamo, M.F.A.* Enantioselective cyclopropanation of (Z)-3-substituted-2-(4-pyridyl)-acrylonitriles catalyzed by cinchona ammonium salts. Org. Biomol. Chem., 2016, 14(11), 3105-3111.

6. Del Fiandra, C., Moccia, M.; Cerulli, V.; Adamo, M.F.A.* Catalytic asymmetric conjugate addition  of  isocyanoacetate to (Z)-3-substituted-2-(4-pyridyl)-acrylonitrile, a reactive class of Michael acceptor. Chem. Commun, 2016, 52 , 1697-1700.

7. Disetti, P., Moccia, M., Salazar-Illera D., Suresh S., Adamo M. F.A* Catalytic enantioselective addition of isocyanoacetate to 3-methyl-4nitro-5-styrilisoxazoles under phase transfer catalysis conditions. Org. Biomol. Chem., 2015,13, 10609-10612.

8. Moccia, M.,*Cortigiani, M., Monasterolo, C., Torri, F., Del Fiandra, C., Fuller, G., Kelly, B., Adamo, M.F.A. * Development and scale up of an organocatalytic enantioselective process to manufacture (S)-Pregabalin. Org. Pro. Res. Dev. 2015, 19(9) 1274-1281.

9. Moccia, M.,* Wells, R. J., Adamo, M.F.A.,* An improved procedure to prepare 3-methyl-4-nitroalkenethylisoxazoles and their reaction under catalytic enantioselective Michael addition with nitromethane. Org. Biomol. Chem.2015,  13, 2192-2195.

10. Piras, L., Moccia, M., Cortigiani, M., Adamo, M.F.A.*,. Cyclopropanation of 5-(1-bromo-2-phenyl-vinyl)-3-methyl-4-nitro-isoxazoles under phase transfer catalysis (PTC) conditions. Catalysts, 2015,5(2), 595-605.

11.Del Fiandra C, Piras L, Fini F, Disetti P, Moccia M, Adamo MFA. Phase transfer catalyzed enantioselective cyclopropanation 4-nitro-5-styrylisoxazoles. Chem. Commun. 2012, 48, 3863-5.

12. Salazar Illera D, Suresh S, Moccia M, Bellini G, Saviano M, Adamo MFA. N-Heterocyclic carbene catalysed homoenolate addition to 3-methyl-4-nitro-5-styrylisoxazoles. Tetrahedron Lett., 2012, 53, 1808-11.

13. Moccia M, Fini F, Scagnetti M, Adamo M F.A. Catalytic enantioselective addition of sodium bisulfite to chalcones. Angew. Chem. Int. Ed. 2011, 50, 6893-6895.

14. Bruschi S, Moccia M, Mauro MFA. Studies on the reactivity of 3-methyl-4-nitro-5-styrylisoxazoles with S-Nucleophiles. Tetrahedron Lett., 2011, 52, 3602-3604.

15. Musumeci D, Bucci E, Roviello GN, Sapio R, Valente M, Moccia M, Bianchi ME, Pedone C. DNA-based strategies for blocking HMGB1 cytokine activity: design, synthesis and preliminary in vitro/in vivo assays of DNA and DNA-like duplexes. Mol. Biosyst., 2011, 7, 1742-52.

16. Adamo FMA, Pergoli R, Moccia M. Alkynyl 2-deoxy-D-riboses,  a cornucopia for generation of families of C-nucleosides. Tetrahedron, 2010, 66, 9242-9251.

17. Moccia M, Roviello GM, Bucci EM, Pedone C, Saviano M.  Synthesis of a L-lysine-based alternate alpha,epsilon-peptide: a novel linear polycation with nucleic acid-binding ability. Int.J. Pharm, 2010, 397, 179-83.